Russell Rebalance: 3 Stocks to Buy Now
- Investors are closely watching the upcoming Russell Reconstitution on June 27,anticipating potential shifts in stock values.
- However, investors should remain cautious and await official announcements, as demonstrated by the decline in Robinhood Markets Inc (NASDAQ:) stock after its S&P 500 denial. Here are three...
- Sprouts Farmers Market Inc (SFM): The natural and organic food retailer has seen its stock (SFM) climb over 500% in five years, fueled by increasing health consciousness.
Russell Reconstitution: Stocks Poised for Growth in 2025
Updated June 21,2025
Investors are closely watching the upcoming Russell Reconstitution on June 27,anticipating potential shifts in stock values. The annual reshuffling of the Russell indexes frequently enough leads to critically important trading activity, especially for small- to mid-cap stocks aiming to climb into the Russell 1000.
However, investors should remain cautious and await official announcements, as demonstrated by the decline in Robinhood Markets Inc (NASDAQ:) stock after its S&P 500 denial. Here are three stocks garnering attention for potential upward movement during this Russell Reconstitution period:
Sprouts Farmers Market Inc (SFM): The natural and organic food retailer has seen its stock (SFM) climb over 500% in five years, fueled by increasing health consciousness. This trend aligns with the “Make America Healthy Again” (MAHA) movement. SFM stock has increased more than 100% in the last year, reaching a market cap of approximately $15 billion. While its P/E ratio exceeds 25x, its niche focus may mitigate headwinds. A recent dip positions it as a buy-the-dip opportunity, finding support at its 50- and 100-day simple moving averages.
insmed inc (INSM): Insmed (NASDAQ: INSM) has surged over 47% recently, driven by positive Phase IIb trial data for its treprostinil palmitil inhalation powder (TPIP) in treating pulmonary arterial hypertension (PAH). The drug met all primary and secondary endpoints.Insmed also announced a $750 million capital raise to expand its pipeline. While short interest remains above 10%, institutional investors have increased their buying, aligning with bullish analyst sentiment since the May earnings report. The biotech stock is one to watch during the Russell Reconstitution.
FTAI
